“Monoclonal-Type” Plastic Antibodies for COVID-19 Treatment: What Is the Idea?

Puoci, Francesco

doi:10.3390/jfb11020043

Cited by 17 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An antibody-based treatment has the potential to provide immediate effect in a COVID positive patient. The spike protein on the SARS-CoV-2 virus is the main target being explored for potential COVID-19 monoclonal antibodies [31].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape

Bhat¹,

Surabathula²,

Pandey³

et al. 2020

Dental

View full text Add to dashboard Cite

Several strains of the novel Coronavirus have been identified and countries around the world are conducting research to identify, map and compare each type. Its infection can manifest with symptoms ranging from uncomplicated nonspecific illness to a more damaging syndrome that include mild to moderate pneumonia (Covid-19 pneumonia broadly categorised into the phenotypes: L-type and H-type); Acute Respiratory Distress Syndrome; Sepsis and Septic shock.Although, this virus has a low mortality rate, the danger lies in its virulence and transmission dynamics. Until date, there has been no drug identified to be efficacious cure for this infection.Using the WHO (World Health Organization) guidelines as a base, various medical institutions are continuously updating their guidelines for the identification and therapeutic management of persons infected with Covid 19, with a strong emphasis on IPC measures. The guidelines also highlight detailed supportive treatment including supplemental oxygen therapy, ventilation, intubation and management of specific complications. The current treatment is tailored to patient centred management for the existing co-morbidities and appreciates a progress in the prognosis. The aim of this article is thus to review salient features of specific therapies being used now and summaries the different clinical trials being conducted so as to stay abreast of the possible treatment modalities.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape

Bhat¹,

Surabathula²,

Pandey³

et al. 2020

Dental

View full text Add to dashboard Cite

show abstract

“…These polymeric materials possess specific recognition properties for target molecules (templates). Some of such MTPAs were developed to target RBD of coronaviruses preventing infection of targeted cells ( 89 ).…”

Section: Covid-19: Therapeutic Approachesmentioning

confidence: 99%

Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19

Majumder

Minko

2021

AAPS J

378

266

View full text Add to dashboard Cite

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.

show abstract

“…MIP has been used as a theranostic system in targeted drug delivery and self-monitoring for cancer cell therapeutics, which can also be exploited against SARS-CoV-2. This technology can be used to synthesize “monoclonal-type” plastic antibodies to combat COVID-19 [ 93 ]. Using MIP, specific monoclonal antibodies can be synthesized to selectively bind the SARS-CoV-2 spike protein, and thus inhibiting the entry of viral particles inside cells.…”

Section: Nanoparticles Against Sars-cov-2: Therapeutic and Vaccine Developmentmentioning

confidence: 99%

Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2

Kamat

Kumari

Jayabaskaran

2021

Journal of Controlled Release

View full text Add to dashboard Cite

The recent outbreak of SARS-CoV-2 has forever altered mankind resulting in the COVID-19 pandemic. This respiratory virus further manifests into vital organ damage. Nanotechnology has been moonlighting in the scientific community to combat several severe diseases. This review highlights the triune of the nano-toolbox in the areas of diagnostics, therapeutics, prevention, and mitigation of SARS-CoV-2. Nanogold test kits have already been on the frontline of rapid detection. Breath tests, magnetic nanoparticle-based nucleic acid detectors, and the use of Raman Spectroscopy present myriads of possibilities in developing point of care biosensors. This will ensure sensitive, affordable, and accessiblemass surveillance. Most of the therapeutics are trying to focus on blocking the viral entry into the cell and fighting with cytokine storm. Nanobodies as vaccines against S and N protein have regained importance. All the vaccines coming with promising phase 3 clinical trials have used nano-delivery systems for delivery of vaccine-cargo. The use of chemically diverse metal, carbon and polymeric nanoparticles, nanocages and nanobubbles demonstrate opportunities to develop anti-viral nanomedicine. Nanotechnology also presents myriads of options for targeted drug delivery. In order to prevent and mitigate the viral spread, high-performance charged nanofiber filters, spray coating of nanomaterials on surfaces, novel materials for PPE kits and facemasks have been developed that accomplish over 90% capture of airborne SARS-CoV-2. Nano polymer-based disinfectants are being tested to make smart-transport for human activities. Despite the promises of this toolbox, challenges in terms of reproducibility, specificity, and efficacy are yet to overcome.

show abstract

“Monoclonal-Type” Plastic Antibodies for COVID-19 Treatment: What Is the Idea?

Abstract: In late December 2019, an outbreak due to a novel coronavirus, initially called 2019-nCoV, was reported in Wuhan, China [...]

Cited by 17 publications

References 15 publications

Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape

Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape

Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19

Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2

Contact Info

Product

Resources

About